17β-hydroxysteroid dehydrogenases 1 and 2: potential markers for breast cancer recurrence and tamoxifen resistance among premenopausal women diagnosed with breast cancer in Denmark.

被引：0

作者：

Collin, Lindsay Jane ^{[1
]}

Kjaersgaard, Anders ^{[2
]}

Ahern, Thomas P. ^{[3
]}

Goodman, Michael ^{[4
]}

McCullough, Lauren E. ^{[4
]}

Waller, Lance A. ^{[4
]}

Christensen, Kristina B. ^{[5
]}

Damkier, Per ^{[6
]}

Hamilton-Dutoit, Stephen J. ^{[5
]}

Lauridsen, Kristina ^{[5
]}

Chistiansen, Peer M. ^{[5
]}

Ejlertsen, Bent ^{[7
]}

Sorensen, Henrik Toft ^{[2
]}

Cronin-Fenton, Deirdre ^{[2
]}

Lash, Timothy L. ^{[4
]}

机构：

[1] Huntsman Canc Inst, Salt Lake City, UT USA

[2] Aarhus Univ, Aarhus, Denmark

[3] Univ Vermont, Burlington, VT USA

[4] Emory Univ, Atlanta, GA 30322 USA

[5] Aarhus Univ Hosp, Aarhus, Denmark

[6] Odense Univ Hosp, Odense, Denmark

[7] Danish Breast Canc Grp, Copenhagen, Denmark

来源：

CANCER RESEARCH | 2021年 / 81卷 / 13期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

757

引用

页数：2

共 50 条

[21] Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer
J Bostner
M Ahnström Waltersson
T Fornander
L Skoog
B Nordenskjöld
O Stål
Oncogene, 2007, 26 : 6997 - 7005
[22] AGR2, an estrogen response gene associated with tamoxifen resistance, is modulated by acolbifene in premenopausal women at high risk for development of breast cancer
Fabian, Carol J.
Phillips, Teresa A.
Kimler, Bruce F.
CANCER RESEARCH, 2022, 82 (04)
[23] Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors
Aubert, R. E.
Stanek, E. J.
Yao, J.
Teagarden, J. R.
Subar, M.
Epstein, R. S.
Skaar, T. C.
Desta, Z.
Flockhart, D. A.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
[24] The Role of ESR1 Gene Polymorphic Markers in the Development of Breast Cancer and Resistance to Tamoxifen Therapy
Lukina, S. S.
Burdennyy, A. M.
Zavarykina, T. M.
Riabchikov, D. A.
Kazubskaya, T. P.
Kruglova, M. P.
Loginov, V., I
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2021, 170 (03) : 350 - 355
[25] The Role of ESR1 Gene Polymorphic Markers in the Development of Breast Cancer and Resistance to Tamoxifen Therapy
S. S. Lukina
A. M. Burdennyy
T. M. Zavarykina
D. A. Riabchikov
T. P. Kazubskaya
M. P. Kruglova
V. I. Loginov
Bulletin of Experimental Biology and Medicine, 2021, 170 : 350 - 355
[26] Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer
Hilborn, Erik
Stal, Olle
Jansson, Agneta
ONCOTARGET, 2017, 8 (18) : 30552 - 30562
[27] 17β-estradiol-induced expression of αEF1 confers tamoxifen resistance in breast cancer
Guo, Shaocong
Hu, Fen
Gao, Yang
Zhu, Tianhui
Yang, Shuang
CANCER RESEARCH, 2012, 72
[28] Association between expression of androgen receptor in tumor tissue and risk of breast cancer recurrence among premenopausal Danish women
Nash, Rebecca
Kjaersgaard, Anders
Christensen, Kristina
Ahern, Thomas
Collin, Lindsay
Hamilton-Dutoit, Stephen
McCullough, Lauren
Schildkraut, Joellen
Sorensen, Henrik
Ward, Kevin
Woolpert, Kirsten
Lash, Timothy
Cronin-Fenton, Deirdre
CANCER RESEARCH, 2024, 84 (09)
[29] A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer
Anders, Carey
Marcom, P. Kelly
Peterson, Bercedis
Gu, Lin
Unruhe, Sue
Welch, Renee
Lyons, Peggy
Kimmick, Gretchen
Shaw, Heather
Snyder, Stacey
Antenos, Monica
Woodruff, Teresa
Blackwell, Kimberly
CANCER INVESTIGATION, 2008, 26 (03) : 286 - 295
[30] Contribution of ABCB1 and CYP2D6 Genotypes to the Outcome of Tamoxifen Adjuvant Treatment in Premenopausal Women With Breast Cancer
Argalacsova, S.
Slanar, O.
Vitek, P.
Tesarova, P.
Bakhouche, H.
Drazdakova, M.
Bartosova, O.
Zima, T.
Pertuzelka, L.
PHYSIOLOGICAL RESEARCH, 2015, 64 : S539 - S547

← 1 2 3 4 5 →